Clozapine for treatment-resistant bipolar disorder: A systematic review

Bipolar Disorders

Volumn 17, Issue 3, 2015, Pages 235-247

  Li, Xian Bin ^a,b   Tang, Yi Lang ^a,c   Wang, Chuan Yue ^a,b   de Leon, Jose ^d,e,f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Eastern State Hospital   (United States)

^e UNIVERSITY OF GRANADA   (Spain)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Bipolar disorder; Clozapine; Treatment resistant

Indexed keywords

CLOZAPINE; LITHIUM; VALPROIC ACID; NEUROLEPTIC AGENT;

AGGRESSION; AGRANULOCYTOSIS; BIPOLAR DISORDER; BLOOD CELL COUNT; BODY WEIGHT DISORDER; BRADYKINESIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONSCIOUS SEDATION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EEG ABNORMALITY; ENURESIS; EVIDENCE BASED PRACTICE; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HAND TREMOR; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERSALIVATION; ILEUS; INCREASED APPETITE; LEUKOPENIA; LONG TERM CARE; MANIA; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORTHOSTATIC HYPERTENSION; OUTCOME ASSESSMENT; PATIENT HARM; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SEIZURE; SLEEP DISORDER; SOCIAL INTERACTION; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESISTANT BIPOLAR DISORDER; TREATMENT WITHDRAWAL; URINE INCONTINENCE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; HUMANS;

EID: 84928166221     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12272     Document Type: Review

References (119)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
2. Marder SR, Van Putten T. Who should receive clozapine? Arch Gen Psychiatry 1988; 45: 865-867.
3. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry Suppl 1992; 17: 46-53.
4. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190.
5. Asenjo Lobos C, Komossa K, Rummel-Kluge C et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Library 2010; CD006633.
6. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962.
7. Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia. CNS Drugs 2012; 26: 491-508.
8. Owen R Jr, Beake B, Marby D, Dessain E, Cole J. Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989; 25: 253.
9. Naber D, Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry 1990; 41: 886-890.
10. Leppig M, Bosch B, Naber D, Hippius H. Clozapine in the treatment of 121 out-patients. Psychopharmacology 1989; 99: S77-S79.
11. Banov MD, Zarate CA Jr, Tohen M et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300.
12. McElroy SL, Dessain EC, Pope HG Jr et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-414.
13. Lindström LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524-529.
14. Frakenburg FR. Clozapine and bipolar disorder. J Clin Psychopharmacol 1993; 13: 289-290.
15. Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994; 36: 338-340.
16. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32: 270-280.
17. Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord 2012; 14: 573-584.
18. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (Suppl. 4): 1-50.
19. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
20. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
21. Hwu H-G, Joyce PR, Karam EG et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293-299.
22. McElroy SL, Frye M, Denicoff K et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998; 49: 119-122.
23. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-566.
24. Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999; 11: 137-140.
25. Dell'Osso B, Mundo E, D'Urso N et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord 2009; 11: 76-81.
26. Erfurth A, Michael N, Stadtland C, Arolt V. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 2002; 45: 33-36.
27. Pacchiarotti I, Mazzarini L, Colom F et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120: 429-440.
28. Gitlin MJ. Treatment-resistant bipolar disorder. Bull Menninger Clin 2001; 65: 26-40.
29. Benedetti A, Di Paolo A, Lastella M et al. Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health 2010; 6: 30-35.
30. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
31. Sharm V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Disord 2008; 111: 100-105.
32. Phillips MR, Zhang J, Shi Q et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet 2009; 373: 2041-2053.
33. Tsai S-Y, Chen C-C, Yeh E-K. Alcohol problems and long-term psychosocial outcome in Chinese patients with bipolar disorder. J Affect Disord 1997; 46: 143-150.
34. Si TM, Shu L, Yu X et al. A cross-sectional study on treatment patterns of bipolar disorders in China in 2006. Chin J Psychiatry 2012; 45: 29-34.
35. Chen XL, Xing BP, Zhang YQ, Jin WD. Atypical antipsychotics in the treatment of elder patients with mania. Herald Med 2008; 27: 672-673.
36. Fan ZG, Chen JM, Lu GH. Comparison analysis of clozapine treatment for 54 cases with mania Chin. J Neurol 1994; 39: 202.
37. Liu YQ, Zhun FY, Yang LZ, Wang RJ, Chen CM. Clinical treatment analysis of 528 cases of affective disorders patients. Chin J Pharmacoepidemiol 1997; 5: 158-161.
38. Wang GY, Dong YM. The investigation and analysis of outpatient drug use in psychiatry. Chin J Modern Drug Application 2007; 1: 44.
39. Liu TB, Gao H, Shen QJ. Clozapine combined with lithium carbonate in the treatment of acute mania. J Clin Psychiatry 2000; 10: 350-351.
40. Zhang L, Chen JD. A double-blind study of clozapine combined with lithium carbonate. J Psychiatry 2002; 15: 40-41.
41. Yan JX. A double-blind clinical trial of add-on clozapine in the treatment of treatment-resistant depression. Clin J Psychol Med 2001; 11: 170-171.
42. Xu XH. One case of treatment-resistant twin mania. J Clin Psychosom Dis 2003; 9: 26.
43. Tan J. The efficacy and safety of lithium and low-dose clozapine treatment for refractory bipolar. Youjiang Med 2010; 38: 150-151.
44. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
45. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169.
46. Si TM, Shu L, Yu X et al. Antipsychotic drug patterns of schizophrenia in China: a cross-sectioned study. Chin J Psychiatry 2004; 37: 152-155.
47. Zhang GP, Wang CY. The one-day survey on psychotropic drug use in 788 psychotic inpatients in Beijing Anding Hospital. Chin J Clin Pharmacol 2001; 17: 287-289.
48. Luo RL, Chen Q. Investigation and analysis of psychotropic in 296 inpatients in one day. J Chin People Health 2009; 21: 1755-1756.
49. Tang YL, Mao PX, Jiang F et al. Clozapine in China. Pharmacopsychiatry 2008; 41: 1-9.
50. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
51. Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14: 863-869.
52. Varadhan KK, Neal KR, Lobo DN. Safety and efficacy of antibiotics compared with appendicectomy for treatment of uncomplicated acute appendicitis: meta-analysis of randomised controlled trials. BMJ 2012; 344: e2156.
53. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: Wiley Online Library, 2008.
54. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JP, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: Cochrane Book Series, 2008: 187-241.
55. Leandro G. Meta-Analysis in Medical Research: The Handbook for the Understanding and Practice of Meta-Analysis. Wiley.com, 2008. Available from: http://www.books.google.com [accessed October 2014].
56. Ried K. Interpreting and understanding meta-analysis graphs: a practical guide. Aust Fam Physician 2006; 35: 635-638.
57. Hoffer ZS, Roth RL, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009; 50: 317-324.
58. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67: 461-467.
59. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000; 61: 329-334.
60. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64: 451-458.
61. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-112.
62. Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry 1994; 55 (Suppl. B): 91-93.
63. Green AI, Tohen M, Patel JK et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157: 982-986.
64. Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 10-14.
65. Kowatch RA, Suppes T, Gilfillan SK, Fuentes RM, Granneman BD, Emlsie GJ. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J Child Adolesc Psychopharmacol 1995; 5: 241-253.
66. Liu NH, Ying D. The clinical observation of clozapine add valproate and propranolol for treatment-resistant depression. Med J Chin People Health 2006; 18: 771.
67. Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156: 702-709.
68. Ketter TA, Kimbrell TA, George MS et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry 2001; 49: 97-109.
69. Vieta E, Reinares M, Corbella B et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001; 21: 469-473.
70. Antonacci DJ, Swartz CM. Clozapine treatment of euphoric mania. Ann Clin Psychiatry 1995; 7: 203-206.
71. Poyurovsky M, Weizman A. Safety and effectiveness of combined ECT and clozapine in treatment-resistant mania. Eur Psychiatry 1996; 11: 319-321.
72. Mahmood T, Devlin M, Silverstone T. Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment. Aust N Z J Psychiatry 1997; 31: 424-426.
73. Chanpattana W. Combined ECT and clozapine in treatment-resistant mania. J ECT 2000; 16: 204-207.
74. Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol 1991; 11: 396-397.
75. Lancon C, Llorca PM. Clozapine in the treatment of refractory rapid cycling bipolar disorder. Encephale 1996; 22: 468-469.
76. Chen CK, Shiah IS, Yeh CB, Mao WC, Chang CC. Combination treatment of clozapine and topiramate in resistant rapid-cycling bipolar disorder. Clin Neuropharmacol 2005; 28: 136-138.
77. Bastiampillai TJ, Reid CE, Dhillon R. The long-term effectiveness of clozapine and lamotrigine in a patient with treatment-resistant rapid-cycling bipolar disorder. J Psychopharmacol 2010; 24: 1834-1836.
78. Gupta M. Clozapine monotherapy for 66 months in treatment resistant bipolar disorder: a case report. J Clin Psychopharmacol 2009; 29: 501-503.
79. Vijay Sagar KJ. Treatment-refractory, juvenile-onset bipolar affective disorder. Ind J Psychiatry 2005; 47: 124-125.
80. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998; 59 (Suppl. 3): 38-43.
81. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bull 1991; 17: 247-261.
82. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996; 153: 417-419.
83. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis-incidence and risk factors in the United States. N J Engl Med 1993; 329: 162-167.
84. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 193-198.
85. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-488.
86. Fan ZY, Cui HS, Shen AZ, Ju FY, Tang M, Bai SZ. 3113 cases of WBC count of psychiatric patients after clozapine treatment. New Drug Clin 1992; 10: 330-331.
87. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 369-371.
88. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5, 629 patients. Neurology 1994; 44: 2247-2249.
89. Haller E, Binder RL. Clozapine and seizures. Am J Psychiatry 1990; 147: 1069-1071.
90. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000; 61 (Suppl. 8): 14-17.
91. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl 1992; 54-59.
92. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-510.
93. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47-S53.
94. Tamminga C, Thaker G, Moran M, Kakigi T. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 (Suppl. B): 102-106.
95. Small JG, Milstein V, Marhenke JD, Hall DD. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987; 48: 263-267.
96. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56: 75-80.
97. Liu TZ, Song SY. A comparative study of clozapine versus lithium in the treatment of mania. Shandong Arch Psychiatry 1990; 3: 21-23.
98. Liu HY, Gong CF, Ma ZL. A controlled study of clozapine, sodium valproate and carbamazepine in the treatment of 84 patients with mania. Health Psychol J 2002; 10: 228-230.
99. Wu YH. Comparative study of clozapine versus olanzapine in the treatment of mania. Pract Chin Clin Med 2004; 21: 34-35.
100. Wei XY, Wang QM, Yang YJ, Liu MY. The comparison of olanzapine and clozapine in the treatment of mania. J Clin Psychol Med 2002; 12: 347-348.
101. Xie WJ, Zhao YM, Li J, Zhou Y, Chen M. A study of aripiprazole versus clozapine in the treatment of mania. Shandong Arch Psychiatry 2006; 19: 2.
102. Liao GS. A comparative study of quetiapine and clozapine in the treatment of mania episode. Med J Chin People Health 2009; 21: 2993-2994.
103. Yan JX, Chu PH, Liu QH, Chu JF, Lv XS, Zhang YQ. Clozapine combined with lithium in the treatment of mania. Chin J Nerv Ment Dis 1997; 23: 104-106.
104. Tao Q, Yang XJ, Wang RQ. A comparative study of lithium and chlorpromazine versus lithium and clozapine in the treatment of mania. Sichuan Arch Psychiatry 1999; 12: 56-57.
105. Zhang GY, Xie QM, Wang YX, Liu CM. Antipsychotics combined with lithium in the treatment of mania. J Clin Psychol Med 2006; 16: 2.
106. Jing YL, Wang LT, Li J. A comparative study of olanzapine and clozapine combined with lithium in the treatment of mania. Shandong Arch Psychiatry 2005; 18: 256-257.
107. Tao H, Jin WD, Liu ZC, Qiu DS, Ma YC, Shen Y et al. Controlled studies on olanzapine or clozapine and stabilizer in patients with mania. J Clin Psychosom Dis 2004; 10: 164-166.
108. Dong YY, Gan JG. Randomized controlled study of clozapine combined lithium versus ziprasidone combined lithium in the treatment of mania. J Pract Med 2010; 26: 1806-1807.
109. Tang XW, Wu H, Chen Q. Randomized controlled trial comparing quetiapine with lithium and clozapine with lithium in the treatment of female patients with mania. Shanghai Arch Psychiatry 2011; 23: 291-298.
110. Chang W, Lin S, Lane H, Hu W, Jann M, Lin H. Clozapine dosages and plasma drug concentrations. J Form Med Assoc 1997; 96: 599-605.
111. Chong S-A, Tan C-H, Khoo Y-M et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 1997; 19: 219-223.
112. Sirot EJ, Knezevic B, Morena GP et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29: 319-326.
113. de Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2012; 8: 311-334.
114. Diaz F, Santoro V, Spina E et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91.
115. Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4-22.
116. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
117. Frye MA, Ketter TA, Altshuler LL et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-104.
118. Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40: 253-258.
119. Quante A, Zeugmann S, Bajbouj M, Anghelescu I. Clozapine in medication- and electroconvulsive therapy-resistant, depressed inpatients: a case series. J Clin Psychopharmacol 2007; 27: 715-717.